

PRESS RELEASE

innate pharma

INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON JUNE 2, 2016 AND THE RELEASE OF ITS REFERENCE DOCUMENT (IN FRENCH)

Marseille, France, April 27, 2016

Innate Pharma (the "Company" - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders ("AGM") on June 2, 2016, at 10:00 am in its headquarters, 117 avenue de Luminy, F-13009 Marseille.

The Notice of Meeting of this Shareholders' Meeting was published this day, in the French official legal bulletin ("BALO"). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this Meeting. It is also available on the Company's website, in the investors' room (<http://www.innate-pharma.com/AGMdocuments>).

All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be available on the Company's website on May 12, 2016.

The 2015 Reference Document (in French) and Financial Report (included in the Reference Document) was released on April 25, 2016 under number D.16-0397, and is available on the website of the Company (<http://innate-pharma.com>) as well as on the website of the AMF, the French stock-market authorities (www.amf-france.org). Hard copies are available upon request to the investor relations department of the Company.

An English translation of the 2015 Reference Document will be made available on Innate Pharma's website during the month of May 2016.

Precision regarding the AGM:


Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to attend.

Shareholders holding "au porteur" (bearer) shares will need to obtain an "attestation de participation" (certificate of shareholding) from their brokers. This "attestation de participation" must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGM in person.

Written questions from shareholders must be received from the day of the publication of the official convocation to the AGM up until four business days prior to the AGM (by registered letter, addressed to the registered office, or by e-mail to investors@innate-pharma.com).

Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French "Code de Commerce") by sending a request:

- by regular mail to Innate Pharma, Shareholders Services, 117 avenue de Luminy, BP 30191, F-13009 Marseilles, France or
- by e-mail to investors@innate-pharma.com.



PRESS RELEASE

innate pharma

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.

The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms.

Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb and AstraZeneca, Sanofi and Novo Nordisk A/S.

Based in Marseille, France, Innate Pharma had 118 employees as at December 31, 2015. The company is listed on Euronext-Paris.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code FR0010331421
Ticker code IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website (www.innate-pharma.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma
Laure-Hélène Mercier
Director, Investor Relations
Tel.: +33 (0)4 30 30 30 87
investors@innate-pharma.com

ATCG Press
Marie Puvieux
Mob.: +33 (0)6 10 54 36 72
presse@atcg-partners.com